ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 106

Antinuclear Antibodies Positive But No Autoimmune Disease

M Herold1 and Werner Klotz2, 1Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria, 2Internal Medicine VI, Innsbruck Medical University, Innsbruck, Austria

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ANA, autoantibodies and health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Antinuclear antibodies (ANAs) are tested in sera of patients suspicious of an autoimmune disorder. ANAs are part in many classification criteria of autoimmune (AI) diseases. In healthy individuals ANAs may also be found and are most often anti-DFS70 antibodies (Mahler M et al. Autoimmun Rev 2012;11:642-5). The frequency of anti-DFS70 antibodies was tested in sera of patients who were hospitalized or attended our outpatient clinic.

Methods:

336 consecutive and ANA positive samples were screened on Hep-2 cells for the presence of a typical DFS70 pattern defined as dense fine speckled staining of nucleoli of interphase cells and intensive staining of the condensed chromosomal material in mitotic cells or similar immunofluorescence patterns (e.g. homogenous, fine speckled, combination of homogenous and fine speckled patterns, centromere and others). Presence of anti-DFS70 autoantibodies was confirmed using a new chemiluminescence immunoassay (CLI; BIO-FLASH – DFS70 Assay; kindly provided by Inova Diagnostics, USA, within an unrestricted research grant).

Results:

A pattern indicative of DFS70 autoantibodies could be found in 103 samples; in 82 of them (80 %) presence of anti-DFS70 autoantibodies could be confirmed by the CLIA vs. 9 in 233 samples (4 %) with other patterns. Numbers of other patterns were 70 with fine speckled, 66 homogenous and fine speckled, 43 homogenous, 4 centromere and 50 with mixed or other patterns.

In 298 of 336 patients a clinical diagnoses was found in the medical records. An autoimmune disease was given in 12 out of 78 patients (15 %) with DFS70 pattern (6 with juvenile arthritis, 5 with rheumatoid arthritis, 1 SLE) vs. 86 out of 220 patients (39 %) with other patterns (31 with SLE, 28 with RA, 2 with ANCA-associated vasculitis, 6 juvenile arthritis, 4 Sjogren’s syndrome, 4 UCDT, 11 other AI diseases ) and 8 out of 71 patients (11 %) with DFS70 autoantibodies in specific immunoassay (3 with juvenile RA, 2 with RA, 2 SLE, 1 patient suspect of MCDT) vs. 88 out of 227 DFS70 negative patients (39 %) (31 with RA, 30 with SLE, 9 juvenile RA, 4 Sjogren’s syndrome, 2 UCDT, 12 with other AI diseases).

Conclusion:

Anti-DFS70 was most often found (85 %) in people without other signs of an autoimmune disorder.


Disclosure:

M. Herold,
None;

W. Klotz,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antinuclear-antibodies-positive-but-no-autoimmune-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology